Browsing NTNU Open by Author "Fløtten, Øystein"
Now showing items 1-14 of 14
-
A comparison of CT based measures of skeletal muscle mass and density from the Th4 and L3 levels in patients with advanced non-small-cell lung cancer
Grønberg, Bjørn Henning; Sjøblom, Bjørg; Wentzel-Larsen, Tore; Baracos, Vickie Elaine; Hjermstad, Marianne Jensen; Aass, Nina Kathrine; Bremnes, Roy M.; Fløtten, Øystein; Bye, Asta; Jordhøy, Marit Slaaen (Journal article; Peer reviewed, 2018)Background: Muscle mass and density assessed from CT-images at the L3 level are prognostic for survival and predict toxicity in cancer patients. However, L3 is not always included on routine CT-scans. We aimed to investigate ... -
Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer: a pooled analysis of two randomized trials
Kristensen, Are Korsnes; Solheim, Tora Skeidsvoll; Fløtten, Øystein; Grønberg, Bjørn Henning (Journal article; Peer reviewed, 2018)Background: Many patients experience toxicity from chemotherapy that may negatively impact their health-related quality of life (HRQoL), but side effects often go undetected by health care personnel. Our aim was to investigate ... -
Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer
Halvorsen, Tarje Onsøien; Sundstrøm, Stein Harald; Fløtten, Øystein; Brustugun, Odd Terje; Brunsvig, Paal Fr.; Aasebø, Ulf; Bremnes, Roy M.; Kaasa, Stein; Grønberg, Bjørn Henning (Journal article; Peer reviewed, 2016)Background: Many patients with limited disease small cell lung cancer (LD SCLC) suffer from comorbidity. Not all patients with comorbidity are offered standard treatment, though there is little evidence for such a policy. ... -
Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group
Strøm, Hans Henrik; Bremnes, Roy M.; Sundstrøm, Stein Harald; Helbekkmo, Nina; Fløtten, Øystein; Aasebø, Ulf (Peer reviewed; Journal article, 2013)Background: The palliative role of chemoradiation in the treatment of patients with locally advanced, inoperable non-small-cell lung cancer stage III and negative prognostic factors remains unresolved. Methods: Patients ... -
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial
Grønberg, Bjørn Henning; Killingberg, Kristin Toftaker; Fløtten, Øystein; Brustugun, Odd; HORNSLIEN, KJERSTI; Madebo, Tesfaye; Langer, Seppo Wang; Schytte, Tine; Nyman, Jan; Risum, Signe; Tsakonas, Georgios; Engleson, Jens; Halvorsen, Tarje Onsøien (Journal article; Peer reviewed, 2021)High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial -
Muscle mass and association to quality of life in non-small cell lung cancer patients
Bye, Asta; Sjøblom, Bjørg; Wentzel-Larsen, Tore; Grønberg, Bjørn Henning; Baracos, Vickie E.; Hjermstad, Marianne Jensen; Aass, Nina Kathrine; Bremnes, Roy M.; Fløtten, Øystein; Jordhøy, Marit Slaaen (Journal article; Peer reviewed, 2017)Background Cancer wasting is characterized by muscle loss and may contribute to fatigue and poor quality of life (QoL). Our aim was to investigate associations between skeletal muscle index (SMI) and skeletal muscle ... -
Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer
Killingberg, Kristin Toftaker; Halvorsen, Tarje Onsøien; Fløtten, Øystein; Brustugun, Odd Terje; HORNSLIEN, KJERSTI; Madebo, Tesfaye; Langer, Seppo W.; Schytte, Tine; Risum, Signe; Tsakonas, Georgios; Nyman, Jan; Engleson, Jens; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2022)Objectives In a randomized phase II trial, twice daily (BID) thoracic radiotherapy (TRT) of 60 Gy/40 fractions improved survival compared with 45 Gy/30 fractions in limited stage small-cell lung cancer (LS SCLC). Notably, ... -
Pleural Empyema Caused by Streptococcus intermedius and Fusobacterium nucleatum: A Distinct Entity of Pleural Infections
Dyrhovden, Ruben; Eagan, Tomas Mikal Lind; Fløtten, Øystein; Siljan, William Ward; Leegaard, Truls Michael; Bø, Bjørnar; Fardal, Hilde; Grøvan, Fredrik; Kildahl-Andersen, Arne; Larssen, Kjersti Wik; Tilseth, Rune; Hjetland, Reidar; Løes, Sigbjørn Suk; Lindemark, Frode; Tellevik, Marit Gjerde; Breistein, Rebecca Irene; Kommedal, Øyvind (Peer reviewed; Journal article, 2023)Background - Many community-acquired pleural infections are caused by facultative and anaerobic bacteria from the human oral microbiota. The epidemiology, clinical characteristics, pathogenesis, and etiology of such ... -
Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer
Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Fløtten, Øystein; Brustugun, Odd Terje; Brunsvig, Paal Fr.; Aasebø, Ulf; Bremnes, Roy M.; Tollåli, Terje; Hornslien, Kjersti; Aksnessæther, Bjørg Y.; Liaaen, Erik Dyb; Sundstrøm, Stein Harald (Journal article; Peer reviewed, 2016)Background: Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small cell lung cancer (LD SCLC). Twice daily TRT is well documented, but not universally implemented – probably mainly ... -
Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC
Halvorsen, Tarje Onsøien; Stokke, Kristin; Killingberg, Kristin Toftaker; Raj, Sunil Xavier; Sørhaug, Sveinung; Brustugun, Odd Terje; Fløtten, Øystein; Helbekkmo, Nina; Hornslien, Kjersti; Madebo, Tesfaye; Fluge, Sverre; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2020)Objectives: Two phase III trials show that maintenance pemetrexed therapy after platinum-doublet chemotherapy prolongs overall survival (OS) and progression free survival (PFS) in advanced non-squamous non-small-cell lung ... -
Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement
Valan, Christine Damgaard; Slagsvold, Jens Erik; Halvorsen, Tarje Onsøien; Herje, Martin; Bremnes, Roy M.; Brunsvig, Paal Fr.; Brustugun, Odd Terje; Fløtten, Øystein; Levin, Nina; Sundstrøm, Stein Harald; Grønberg, Bjørn Henning (Journal article; Peer reviewed, 2018)Background/Aim: There are several definitions of limited disease (LD) in small cell lung cancer (SCLC), differing with respect to N3 disease accepted. We analyzed patients from a randomized trial comparing two schedules ... -
Trajectory of health-related quality of life during the last year of life in patients with advanced non-small–cell lung cancer
Kristensen, Are Korsnes; Grønberg, Bjørn Henning; Fløtten, Øystein; Kaasa, Stein; Solheim, Tora S (Peer reviewed; Journal article, 2022)Background The aims of this study were to assess the trajectory of health-related quality of life (HRQOL) during the last year of life in patients with advanced non-small–cell lung cancer (NSCLC) and to explore when and ... -
Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer
Halvorsen, Tarje Onsøien; Herje, Martin; Levin, Nina; Bremnes, Roy M.; Brustugun, Odd Terje; Fløtten, Øystein; Kaasa, Stein; Sundstrøm, Stein Harald; Grønberg, Bjørn Henning (Journal article; Peer reviewed, 2016)Objectives Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small-cell lung cancer (LD SCLC). TRT should start as early as possible, often meaning with the second course due to ... -
Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group
Fløtten, Øystein; Grønberg, Bjørn Henning; Bremnes, Roy M.; Amundsen, Tore; Sundstrøm, Stein Harald; Rolke, Heidi; HORNSLIEN, KJERSTI; Wentzel-Larsen, Tore; Aasebø, Ulf; von Plessen, Christian (Journal article; Peer reviewed, 2012)Background: Platinum-based doublet chemotherapy is the standard first-line treatment for advanced non-small cell lung cancer (NSCLC), but earlier studies have suggested that non-platinum combinations are equally effective ...